Navigation Links
Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
Date:3/12/2009

s, have shown reduction in such clinical events, but events continue to occur despite these therapies. There is, thus, a need for novel agents that specifically modify the actions of thrombin, the most potent activator of platelets.

TRA binds selectively to the thrombin receptor on platelets (PAR-1), and is therefore a member of a potentially new class of drugs called thrombin receptor antagonists.

Importantly, Schering-Plough's TRA is being investigated to determine whether it has the potential to provide clinical benefit through inhibition of this thrombin-mediated platelet activation without the liability of increased bleeding (when added to standard of care), a tendency associated with drugs that block thromboxane or ADP pathways. Specifically, this compound is being investigated as an oral antiplatelet agent for patients with established vascular disease, with the intent to demonstrate incremental benefit when given with current standard antiplatelet (including aspirin and clopidogrel) and other antithrombotic therapies, with no significant increase in bleeding. Clinical studies have shown no increase in bleeding time or prolongation in coagulation times (aPTT or PT) with TRA.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

SCHERI
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
2. Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
3. Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
4. Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
5. Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting
6. Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors
7. Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
8. Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
9. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
10. Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
11. Berlin Hearts EXCOR(R) Pediatric Receives Unconditional Investigational Device Exemption (IDE) Approval
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... , Sept. 15, 2014  Patients in today,s ... care more frequently in an outpatient setting versus a ... curve and to ensure that patients continue to receive ... the launch of its new internal medicine residency program. ... more often in office, clinic and even virtual settings. ...
(Date:9/15/2014)... , Sept. 15, 2014  Valeant Pharmaceuticals International, Inc. ... its wholly owned subsidiary, Valeant Pharmaceuticals International, will redeem ... of its 6.75% Senior Notes due 2017, CUSIP Nos. ... 2014 and has mailed an irrevocable notice of redemption ... a copy of the irrevocable notice of redemption with ...
(Date:9/15/2014)... , Sept. 15, 2014 myMatrixx has extended ... Stanos with an expanded role that includes direct ... Dr. Stanos, a nationally recognized physiatrist and pain management ... to rehabilitation and workers, compensation, is Board Certified in ... American Board of Pain Medicine and subspecialty boarded by ...
Breaking Medicine Technology:Kaiser Permanente Hawaii Launches New Internal Medicine Residency Program 2Kaiser Permanente Hawaii Launches New Internal Medicine Residency Program 3Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017 2myMatrixx Announces Expanded Role for Medical Director Steven P. Stanos, Jr., DO 2
... 2009 Convention -- When Shawnae Jebbia won the Miss USA ... career. She appeared at events throughout the world, worked as ... world unexpectedly changed when she was diagnosed with hearing loss. ... had a difficult time understanding and accepting the sudden hearing ...
... eResearchTechnology, Inc. (ERT), (Nasdaq: ERES ), a leading provider ... medical device and related industries, announced today results for the ... Unless otherwise noted, all comparative numbers refer to changes from ... , Financial highlights for the third quarter of 2009: ...
Cached Medicine Technology:Former Miss USA Shawnae Jebbia Shines with Siemens Pure 2Former Miss USA Shawnae Jebbia Shines with Siemens Pure 3ERT Reports Third Quarter 2009 Results 2ERT Reports Third Quarter 2009 Results 3ERT Reports Third Quarter 2009 Results 4ERT Reports Third Quarter 2009 Results 5ERT Reports Third Quarter 2009 Results 6ERT Reports Third Quarter 2009 Results 7ERT Reports Third Quarter 2009 Results 8ERT Reports Third Quarter 2009 Results 9ERT Reports Third Quarter 2009 Results 10ERT Reports Third Quarter 2009 Results 11ERT Reports Third Quarter 2009 Results 12ERT Reports Third Quarter 2009 Results 13
(Date:9/16/2014)... Current students of Ramtha’s School of Enlightenment are ... Oct. 20-26 to further their studies. , The Capstone ... remarkable “Masters of Divine Jazz” World Tour which featured ... Korea, Mexico, and South Africa. Cost of the 6-day ... and for seniors age 65 and older. , The ...
(Date:9/16/2014)... September 16, 2014 The global market ... 1,129.8 million by 2020, growing at an estimated CAGR ... new study by Grand View Research, Inc. A growing ... of cost curbing initiatives undertaken by medical device manufacturers ... period. In addition, this technology serves as an effective ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Dr. Eric ... launch of ACLsurgeryLA.com , a specialty website devoted ... As an avid sports lover and athlete, Dr. ... treatment and recovery from injuries to maintain active, healthy ... offer patients a resource dedicated specifically to ACL ...
(Date:9/16/2014)... On September 14, the HearStrong Foundation ... Bills Alumni Foundation VIP Tailgate event outside Ralph Wilson ... NFL Hall-of-Famer Joe DeLamielleure, who also experiences hearing ... her dedication in overcoming hearing difficulties to achieve her ... community to do the same. , Nominated by Hearing ...
(Date:9/16/2014)... September 16, 2014 Recently, UWDress.com, an ... occasion gowns, has announced its special offer for ... company’s fashionable cocktail dresses at a low rate. More ... a discounted shipping cost. , UWDress.com has promised ... clients are able to find the most fashionable items. ...
Breaking Medicine News(10 mins):Health News:Ramtha School Presents Capstone Event in Yelm Oct. 20-26 2Health News:Healthcare 3D Printing Market By Application, By Technology And By Raw Materials Is Expected To Reach USD 1,129.8 Million By 2020: Grand View Research, Inc 2Health News:Healthcare 3D Printing Market By Application, By Technology And By Raw Materials Is Expected To Reach USD 1,129.8 Million By 2020: Grand View Research, Inc 3Health News:Healthcare 3D Printing Market By Application, By Technology And By Raw Materials Is Expected To Reach USD 1,129.8 Million By 2020: Grand View Research, Inc 4Health News:Healthcare 3D Printing Market By Application, By Technology And By Raw Materials Is Expected To Reach USD 1,129.8 Million By 2020: Grand View Research, Inc 5Health News:Healthcare 3D Printing Market By Application, By Technology And By Raw Materials Is Expected To Reach USD 1,129.8 Million By 2020: Grand View Research, Inc 6Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 2Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 3Health News:The HearStrong Foundation and the Buffalo Bills Alumni Foundation Celebrated HearStrong Champion During 2014 Alumni Weekend 2Health News:UWDress.com: Cheap Cocktail Gowns For The Global Market 2
... the July issue of the urology journal BJU International, nearly ... a drug known to treat problems of erection. The users ... ,And 70 per cent of family doctors who ... drug feedback form felt the drug wasn't effective. ...
... early as possible in an effort to reverse its ... leading// cause of disability in people over the age ... have been able to treat the disease and offer ... identified telltale, genetic signs that indicate the early onset ...
... salaries of doctors participating in the anti-quota stir was likely to ... to do so was issued on the direction of Director P ... who was asked to explain the reason behind the order to ... was asked to relinquish charge as Registrar by the Director on ...
... country have complained of failed tubectomy birth-control surgeries and ... Pradesh couple has demanded compensation for two failed tubectomy ... complained that she has become pregnant despite the operation. ... in Himachal Pradesh's Shimla district has urged Chief Minister ...
... disorders, here is a cure for you. Store cord blood ... child to ensure a speedy recovery for your family. // ... first cord blood stem cell in India which will store ... of stem cells that can be used in many ways ...
... Probing the effects of the Chernobyl disaster that took place ... radioactivity are not as harmful// as it is thought to ... exists a certain level of toleration or limit of radioactive ... might stir up a debate over nuclear issues that are ...
Cached Medicine News:Health News:Erection Drug Was Not Useful to Two-Thirds of Its Users 2Health News:Erection Drug Was Not Useful to Two-Thirds of Its Users 3Health News:Researchers Beginning to Identify Genetic Culprits of Arthritis 2Health News:Women Complains of Failed Tubectomy from Two Different States 2
Aaron 1250 is a multipurpose electrosurgical generator with monopolar and bi-polar functions....
Bipolar foot activated forceps....
Cushing bayonet....
Bipolar hand activated forceps....
Medicine Products: